SCHEMBL6482686

SCHEMBL6482686

CCOC(=O)CC(=O)NCCc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 2/20 0.64
HDAC4 P56524 2/20 0.64
HDAC1 Q13547 2/20 0.64
HDAC2 Q92769 2/20 0.64
HDAC10 Q969S8 2/20 0.64
HDAC11 Q96DB2 2/20 0.64
HDAC8 Q9BY41 2/20 0.64
HDAC6 Q9UBN7 2/20 0.64
HDAC9 Q9UKV0 2/20 0.64
NCOR2 Q9Y618 2/20 0.64
HDAC7 Q8WUI4 1/20 0.64
HDAC5 Q9UQL6 1/20 0.64
TAAR1 Q96RJ0 2/20 0.53
ALDH1A1 P00352 2/20 0.53
MAPT P10636 3/20 0.53
RAB9A P51151 3/20 0.53
KDM4E B2RXH2 1/20 0.53
POLB P06746 1/20 0.53
PPID Q08752 1/20 0.52
NPC1 O15118 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4657634 0.85 LTA4H (0.59) TAAR1ALDH1A1MAPTRAB9AKDM4E
SCHEMBL2087667 0.84 PPID (0.68) ALDH1A1MAPTPOLBPPIDSMN1; SMN2
SCHEMBL7051374 0.84 KMT2A (0.72) MAPTPOLBSMN1; SMN2MEN1KMT2A
SCHEMBL18765240 0.82 SIRT2 (0.60) HDAC3HDAC4HDAC1HDAC2HDAC10
SCHEMBL8743242 0.82 POLB (0.55) HDAC3HDAC4HDAC1HDAC2HDAC10
SCHEMBL6476422 0.82 MTNR1A (0.63) ALDH1A1KDM4ESMN1; SMN2MTNR1AMTNR1B
SCHEMBL158220 0.82 HDAC3 (0.78) HDAC3HDAC4HDAC1HDAC2HDAC10
SCHEMBL15598341 0.82 HDAC3 (0.73) HDAC3HDAC4HDAC1HDAC2HDAC10
SCHEMBL11183509 0.82 TP53 (0.47) HDAC3HDAC4HDAC1HDAC2HDAC10
SCHEMBL15598347 0.81 HDAC3 (0.85) HDAC3HDAC4HDAC1HDAC2HDAC10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6930114-B2 Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors BAYER PHARMACEUTICALS CORPORATION (US) 2005-08-16 US disclosed
US-20040138249-A1 Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors BAYER PHARMACEUTICALS CORPORATION 2004-07-15 US disclosed
EP-1347973-A1 PYRROLO (2.1-A) DIHYDROISOQUINOLINES AND THEIR USE AS PHOSPHODIESTERASE 10A INHIBITORS Bayer Aktiengesellschaft (DE) 2003-10-01 EP disclosed
WO-2002048144-A1 PYRROLO (2.1-A) DIHYDROISOQUINOLINES AND THEIR USE AS PHOSPHODIESTERASE 10A INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2002-06-20 WO disclosed
US-4407797-A ANTIULCER AGENT RHONE-POULENC SANTE (FR) 1983-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138249-A1 Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors PDE7B, PDE2A, PDE5A HDAC3 855/4885HDAC4 603/4885HDAC1 118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.